Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

Schnell, Oliver; Standl, Eberhard; Catrinoiu, Doina; Genovese, Stefano; Lalic, Nebojsa; Skra, Jan; Valensi, Paul; Ceriello, Antonio
February 2016
Cardiovascular Diabetology;2/18/2016, Vol. 15, p1
Academic Journal
The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich (http://www.dcvd.org).


Related Articles

  • MedSurg Minute.  // MEDSURG Nursing;Aug99, Vol. 8 Issue 4, p227 

    Offers information on cardiovascular disease as a complication of diabetes. Significance of early diagnosis and intervention; Statistics on the incidence of atherosclerotic damage to the coronary arteries in people with diabetes.

  • Get more aggressive with treatments to cut heart risk. Gebhart, Fred // Drug Topics;10/6/2003 Supplement, Vol. 147 Issue 19, p13s 

    Reports on the importance of aggressive diabetes treatment to the prevention of cardiovascular complications. Research on the effectiveness of multiple treatments; Implications for pharmacy-based diabetes treatment clinics.

  • Excess mortality in a population with diabetes and the impact of material deprivation. Roper, Nick A; Bilous, Rudy W; Kelly, William F; Unwin, Nigel C; Connolly, Vincent M // BMJ: British Medical Journal (International Edition);06/09/2001, Vol. 322 Issue 7299, p1389 

    Mortality among people with diabetes is increased even in the most affluent group, and this excess increases with worsening material deprivation

  • Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. GERSTEIN, HERTZEL C.; AMBROSIUS, WALTER T.; DANIS, RONALD; ISMAIL-BEIGI, FARAMARZ; CUSHMAN, WILLIAM; CALLES, JORGE; BANERJI, MARYANN; SCHUBART, ULRICH; CHEW, EMILY Y. // Diabetes Care;May2013, Vol. 36 Issue 5, p1266 

    OBJECTIVE--Both the presence of diabetic retinopathy and its severity are significantly associated with future cardiovascular (CV) events. Whether its progression is also linked to incident CV outcomes hasn't been assessed. RESEARCH DESIGN AND METHODS--The relationship between retinopathy, its...

  • Role of the Endocannabinoid System in Management of Patients with Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. Stephen Davis; Jennifer Perkins // Endocrine Practice;Nov2007, Vol. 13 Issue 7, p790 

    Objective: To review the role of the endogenous cannabinoid system (ECS) in the peripheral and central regulation of food intake, appetite, and energy storage and discuss the potential for the ECS to be an important target for lowering cardiovascular risk.Methods: Materials used for this article...

  • Managing diabetes and cardiovascular risk. Buckley, Bruce // Drug Topics;10/1/2001 Supplement, Vol. 145 Issue 19, p27 

    Deals with the efforts of pharmacists to collaborate with physicians and other healthcare providers in treating type 2 diabetes and controlling the risk factors for cardiovascular disease. Information on the pharmacotherapy consult service offered by pharmacists Joseph Saseen and Laura Borgelt;...

  • Improving Diabetes Management and Cardiovascular Risk Factors Through Peer-Led Self-management Support Groups in Western Kenya. Park, Paul H.; Wambui, Charity K.; Atieno, Sabina; Egger, Joseph R.; Misoi, Lawrence; Nyabundi, Jack S.; Pastakia, Sonak D.; Bloomfield, Gerald S.; Kamano, Jemima H. // Diabetes Care;Aug2015, Vol. 38 Issue 8, pe110 

    The article discusses a study which evaluated the impact of a 6-month diabetes self-management support (DSMS) intervention on diabetes mellitus (DM) and cardiovascular disease risk factors in western Kenya. Topics covered include the association of sex, education, peer group, tribe, glucometer...

  • ROSIGLITAZONEA JOURNEY THAT NEVER COMPLETED. Gopala, Anjali; Sharma, Vinek Kumar; Ganti, Subrahmanya Sarma // International Journal of Pharmacy & Pharmaceutical Sciences;2010 Supplement 2, Vol. 2 Issue S2, p7 

    Diabetes is the major cause of mortality and morbidity leading to cardiovascular and other related complications. Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription factors of nuclear hormone receptor super family comprising of three subtypes such as PPARα,...

  • The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus. Yousefzadeh, Pegah; Xiangbing Wang // Journal of Diabetes Research;2013, p1 

    Objective. To review the current literature investigating the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk factors of cardiovascular disease (CVD). Methods. We conducted a search of PubMed and MEDLINE database, using the term DPP-4 inhibitor in combination with the following...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics